Get the Stockscreener App
3.13
0.00%
0.00
Pre-market:
3.05
-0.08
-2.56%
Veru Inc stock is traded at $3.13, with a volume of 686.82K.
It is up +0.00% in the last 24 hours and up +48.34% over the past month.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
See More
Previous Close:
$3.13
Open:
$3.14
24h Volume:
686.82K
Relative Volume:
0.40
Market Cap:
$50.24M
Revenue:
$3.86M
Net Income/Loss:
$-19.20M
P/E Ratio:
-4.3006
EPS:
-0.7278
Net Cash Flow:
$-24.88M
1W Performance:
+0.97%
1M Performance:
+48.34%
6M Performance:
+28.28%
1Y Performance:
-47.82%
1-Day Range:
$2.96
$3.1988
1-Week Range:
$2.85
$3.34
52-Week Range:
$2.05
$7.33
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
3.13 | 50.24M | 3.86M | -19.20M | -24.88M | -0.7278 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Canaccord Genuity | Buy |
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
This small-cap biotech just soared over 160% — what is the Novo Nordisk connection? - MSN
Veru teams up with Novo Nordisk for obesity combination therapy trial (VERU) - MSN
Veru Inc. (VERU) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Declines Amid Pre-Revenue StatusROIC Trend Report - newsline.com
Why is Veru stock rising 10% today? - Investing.com
Why is Veru stock rising 10% today? By Investing.com - Investing.com Canada
Earnings call transcript: Veru Inc Q2 2026 shows improved financials - MSN
VERU Q1 2026 Earnings: EPS Beat by 58.72% Amidst Market SkepticismPre-Earnings Setup - newsline.com
Wall Street sees huge upside as Novo Nordisk backs biotech company - thestreet.com
Veru And 2 Other Intriguing Penny Stocks To Watch - Sahm
Novo Nordisk's Mixed Bag: Zenagamtide Data Delights, CagriSema Stumbles, Veru Deal Emerges - AD HOC NEWS
Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle - simplywall.st
Veru (NASDAQ: VERU) Stock Price Surges Over 160% After Clinical Supply Deal With Novo Nordisk (NYSE: NVO) - foreignpolicyjournal.com
Veru (VERU) Stock; Surges 88% as Novo Nordisk Partners on Wegovy-Supported Clinical Trial - MEXC
Veru Stock Surges 167% After Novo Nordisk Backs Its Obesity Drug - MEXC
Veru (VERU) Stock Rockets 167% on Novo Nordisk Obesity Drug Partnership - MEXC
Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause - TechStock²
Veru (VERU) Stock Explodes 167% on Novo Nordisk Obesity Drug Partnership - MoneyCheck
Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial - Yahoo Finance
Veru shares jump after Novo Nordisk deal draws traders - TechStock²
Veru stock holds at Outperform as Oppenheimer cites Novo deal - Investing.com
Veru (VERU) Stock Price, Quote, Charts & News - Invezz
Veru (VERU) surges 161.8% after disclosing Novo Nordisk Wegovy supply deal for obesity study - Quiver Quantitative
VERU Maintained by Canaccord Genuity -- Price Target Steady at $25 - GuruFocus
Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge - Moomoo
Veru pact with Novo ‘significant event,’ says Canaccord - TipRanks
Veru announces clinical supply agreement with Novo Nordisk - TipRanks
This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection? - Stocktwits
Why is Veru stock surging today? By Investing.com - Investing.com Canada
Veru Inc. Enters Clinical Supply Agreement with Novo Nordisk for Phase 2B Plateau Clinical Study - marketscreener.com
Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU) - Yahoo Finance
Veru, Novo Nordisk partner on enobosarm-Wegovy trial - TipRanks
Veru (NASDAQ: VERU) secures Novo Nordisk Wegovy supply for Phase 2b obesity trial - Stock Titan
Acute Respiratory Distress Syndrome Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeu - Barchart
VERU Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Share UptickEarnings Surprise Report - newsline.com
Veru Inc. (VERU) Edges Higher as Stock Holds Above Key Support LevelPost-Earnings Moves - newsline.com
Veru 2Q Loss $2.74M >VERU - Moomoo
Veru Inc. Holds Steady Near Support Amid Low VolatilityEarnings Breakout Stocks - The Legal Advocate
VERU Technical Analysis | Trend, Signals & Chart Patterns | VERU INC (NASDAQ:VERU) - ChartMill
Veru Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Call Transcript - The Legal Advocate
VERU - Finviz
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):